Compare SOBR & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOBR | CDT |
|---|---|---|
| Founded | 2004 | 2019 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.4M |
| IPO Year | 2008 | N/A |
| Metric | SOBR | CDT |
|---|---|---|
| Price | $0.59 | $2.92 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 22.3M | 289.1K |
| Earning Date | 04-10-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 103.55 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $437,421.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 105.62 | N/A |
| 52 Week Low | $0.35 | $0.30 |
| 52 Week High | $4.39 | $11.00 |
| Indicator | SOBR | CDT |
|---|---|---|
| Relative Strength Index (RSI) | 44.46 | 69.74 |
| Support Level | N/A | $2.66 |
| Resistance Level | $0.94 | $4.50 |
| Average True Range (ATR) | 0.33 | 0.21 |
| MACD | -0.04 | 0.35 |
| Stochastic Oscillator | 9.82 | 74.58 |
Sobr Safe Inc is a hardware and software company. The Company integrates proprietary software, SOBRsafeTM, with its patented touch-based personal alcohol awareness tracking products, SOBRcheckTM and SOBRsure, enabling non-invasive personal alcohol awareness tracking, biometric identity verification, and qualified, real-time cloud-based, informational alerts and reporting. It operates as a single segment designed to enable customers to purchase products directly through channel partners, sales agents or through its enterprise and consumer digital channels. Currently its principal markets are located in North America.
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.